Eli Lilly and Incyte Receive FDA's EUA for Baricitinib + Remdesivir to Treat Hospitalized Patients with COVID-19
Shots:
- The EUA is based on ACCT-2 study assessing baricitinib (4mg- qd for 14 days or until hospital discharge) in combination with remdesivir vs PBO with remdesivir in hospitalized patients with/ out oxygen requirements
- Result: Median time to recovery from 8-7days (12.5% improvement)- patients who progressed to ventilation (23% vs 28%)- patients who died @day29 (4.7% vs 7.1%) with a relative reduction of 35%; better clinical status @day15
- This marks the second Lilly therapy to be granted a EUA- in addition to neutralizing Ab EUA for high-risk non-hospitalized patients- increasing the number of treatment options for COVID-19 patients at different stages of the disease
Ref: Eli Lilly | Image: Eli Lilly
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com